

MMWR™

MORBIDITY AND MORTALITY WEEKLY REPORT

CDC
Surveillance
Summaries

**Malaria Surveillance —
United States, 1994**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control
and Prevention (CDC)
Atlanta, Georgia 30333



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

- General: Centers for Disease Control and Prevention. *CDC Surveillance Summaries*, October 17, 1997. MMWR 1997;46(No. SS-5).
- Specific: [Author(s)]. [Title of particular article]. In: *CDC Surveillance Summaries*, October 17, 1997. MMWR 1997;46(No. SS-5):[inclusive page numbers].

Centers for Disease Control and Prevention David Satcher, M.D., Ph.D.
Director

The production of this report as an *MMWR* serial publication was coordinated in:

Epidemiology Program Office..... Stephen B. Thacker, M.D., M.Sc.
Director

Richard A. Goodman, M.D., M.P.H.
Editor, MMWR Series

Denise Koo, M.D., M.P.H.
Associate Editor, CDC Surveillance Summaries

Office of Scientific and Health Communications (Proposed)

CDC Surveillance Summaries Suzanne M. Hewitt, M.P.A.
Managing Editor

Rachel J. Wilson
Lanette B. Wolcott
Project Editors

Morie M. Higgins
Peter M. Jenkins
Visual Information Specialists

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Copies can be purchased from Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325. Telephone: (202) 512-1800.

Contents

Reports Published in <i>CDC Surveillance Summaries</i> Since January 1, 1985	ii
Introduction	2
Methods	3
Results	4
Discussion	15
References	16
Appendix	17
State and Territorial Epidemiologists and Laboratory Directors	Inside back cover

Reports Published in *CDC Surveillance Summaries* Since January 1, 1985

Subject	Responsible CIO/Agency*	Most Recent Report
Abortion	NCCDPHP	1997; Vol. 46, No. SS-4
AIDS/HIV		
Distribution by Racial/Ethnic Group	NCID	1988; Vol. 37, No. SS-3
Among Black & Hispanic Children & Women of Childbearing Age	NCEHIC	1990; Vol. 39, No. SS-3
Behavioral Risk Factors	NCCDPHP	1997; Vol. 46, No. SS-3
Birth Defects		
B.D. Monitoring Program (see also Malformations)	NCEH	1993; Vol. 42, No. SS-1
Contribution of B.D. to Infant Mortality Among Minority Groups	NCEHIC	1990; Vol. 39, No. SS-3
Breast & Cervical Cancer	NCCDPHP	1992; Vol. 41, No. SS-2
<i>Campylobacter</i>	NCID	1988; Vol. 37, No. SS-2
Chancroid	NCPS	1992; Vol. 41, No. SS-3
Chlamydia	NCPS	1993; Vol. 42, No. SS-3
Cholera	NCID	1992; Vol. 41, No. SS-1
Chronic Fatigue Syndrome	NCID	1997; Vol. 46, No. SS-2
Congenital Malformations, Minority Groups	NCEHIC	1988; Vol. 37, No. SS-3
Contraception Practices	NCCDPHP	1992; Vol. 41, No. SS-4
Cytomegalovirus Disease, Congenital	NCID	1992; Vol. 41, No. SS-2
Dengue	NCID	1994; Vol. 43, No. SS-2
Dental Caries & Periodontal Disease Among Mexican-American Children	NCPS	1988; Vol. 37, No. SS-3
Developmental Disabilities	NCEH	1996; Vol. 45, No. SS-2
Diabetes Mellitus	NCCDPHP	1993; Vol. 42, No. SS-2
Dracunculiasis	NCID	1992; Vol. 41, No. SS-1
Ectopic Pregnancy	NCCDPHP	1993; Vol. 42, No. SS-6
Elderly, Hospitalizations Among	NCCDPHP	1991; Vol. 40, No. SS-1
Endometrial & Ovarian Cancers	EPO, NCCDPHP	1986; Vol. 35, No. 2SS
<i>Escherichia coli</i> O157	NCID	1991; Vol. 40, No. SS-1
Evacuation Camps	EPO	1992; Vol. 41, No. SS-4
Family Planning Services at Title X Clinics	NCCDPHP	1995; Vol. 44, No. SS-2
Foodborne Disease	NCID	1996; Vol. 45, No. SS-5
Gonorrhea & Syphilis, Teenagers	NCPS	1993; Vol. 42, No. SS-3
Hazardous Substances Emergency Events	ATSDR	1994; Vol. 43, No. SS-2
Health Surveillance Systems	IHPO	1992; Vol. 41, No. SS-4
Hepatitis	NCID	1985; Vol. 34, No. 1SS
Homicide	NCEHIC	1992; Vol. 41, No. SS-3
Homicides, Black Males	NCEHIC	1988; Vol. 37, No. SS-1
Hysterectomy	NCCDPHP	1997; Vol. 46, No. SS-4
Infant Mortality (see also National Infant Mortality; Birth Defects; Postneonatal Mortality)	NCEHIC	1990; Vol. 39, No. SS-3
Influenza	NCID	1997; Vol. 46, No. SS-1
Injury		
Death Rates, Blacks & Whites	NCEHIC	1988; Vol. 37, No. SS-3
Drownings	NCEHIC	1988; Vol. 37, No. SS-1
Falls, Deaths	NCEHIC	1988; Vol. 37, No. SS-1

***Abbreviations**

ATSDR	Agency for Toxic Substances and Disease Registry
CIO	Centers/Institute/Offices
EPO	Epidemiology Program Office
IHPO	International Health Program Office
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEH	National Center for Environmental Health
NCEHIC	National Center for Environmental Health and Injury Control
NCID	National Center for Infectious Diseases
NCIPC	National Center for Injury Prevention and Control
NCPS	National Center for Prevention Services
NIOSH	National Institute for Occupational Safety and Health
NIP	National Immunization Program

Reports Published in *CDC Surveillance Summaries* Since January 1, 1985 — Continued

Subject	Responsible CIO/Agency*	Most Recent Report
Firearm-Related Deaths, Unintentional	NCEHIC	1988; Vol. 37, No. SS-1
Head & Neck	NCIPC	1993; Vol. 42, No. SS-5
In Developing Countries	NCEHIC	1992; Vol. 41, No. SS-1
In the Home, Persons <15 Years of Age	NCEHIC	1988; Vol. 37, No. SS-1
Motor Vehicle-Related Deaths	NCEHIC	1988; Vol. 37, No. SS-1
Objectives of Injury Control, State & Local	NCEHIC	1988; Vol. 37, No. SS-1
Objectives of Injury Control, National	NCEHIC	1988; Vol. 37, No. SS-1
Residential Fires, Deaths	NCEHIC	1988; Vol. 37, No. SS-1
Tap Water Scalds	NCEHIC	1988; Vol. 37, No. SS-1
Lead Poisoning, Childhood	NCEHIC	1990; Vol. 39, No. SS-4
Low Birth Weight	NCCDPHP	1990; Vol. 39, No. SS-3
Malaria	NCID	1997; Vol. 46, No. SS-5
Measles	NCPS	1992; Vol. 41, No. SS-6
Meningococcal Disease	NCID	1993; Vol. 42, No. SS-2
Mining	NIOSH	1986; Vol. 35, No. 2SS
Mumps	NIP	1995; Vol. 44, No. SS-3
National Infant Mortality (see also Infant Mortality; Birth Defects)	NCCDPHP	1989; Vol. 38, No. SS-3
<i>Neisseria gonorrhoeae</i> , Antimicrobial Resistance in	NCPS	1993; Vol. 42, No. SS-3
Neural Tube Defects	NCEH	1995; Vol. 44, No. SS-4
Nosocomial Infection	NCID	1986; Vol. 35, No. 1SS
Occupational Injuries/Disease		
Asthma	NIOSH	1994; Vol. 43, No. SS-1
Hazards, Occupational	NIOSH	1985; Vol. 34, No. 2SS
In Meatpacking Industry	NIOSH	1985; Vol. 34, No. 1SS
Silicosis	NIOSH	1993; Vol. 42, No. SS-5
State Activities	NIOSH	1987; Vol. 36, No. SS-2
Parasites, Intestinal	NCID	1991; Vol. 40, No. SS-4
Pediatric Nutrition	NCCDPHP	1992; Vol. 41, No. SS-7
Pertussis	NCPS	1992; Vol. 41, No. SS-8
Plague	NCID	1985; Vol. 34, No. 2SS
Plague, American Indians	NCID	1988; Vol. 37, No. SS-3
Poliomyelitis	NCPS	1992; Vol. 41, No. SS-1
Postneonatal Mortality	NCCDPHP	1991; Vol. 40, No. SS-2
Pregnancy Nutrition	NCCDPHP	1992; Vol. 41, No. SS-7
Pregnancy-Related Mortality	NCCDPHP	1997; Vol. 46, No. SS-4
Pregnancy, Teenage	NCCDPHP	1993; Vol. 42, No. SS-6
Rabies	NCID	1989; Vol. 38, No. SS-1
Racial/Ethnic Minority Groups	Various	1990; Vol. 39, No. SS-3
Respiratory Disease	NCEHIC	1992; Vol. 41, No. SS-4
Rotavirus	NCID	1992; Vol. 41, No. SS-3
<i>Salmonella</i>	NCID	1988; Vol. 37, No. SS-2
Sexually Transmitted Diseases in Italy	NCPS	1992; Vol. 41, No. SS-1
Silicosis		1997; Vol. 46, No. SS-1
Smoking	NCCDPHP	1990; Vol. 39, No. SS-3
Smoking-Attributable Mortality	NCCDPHP	1994; Vol. 43, No. SS-1
Tobacco Control Laws, State	NCCDPHP	1995; Vol. 44, No. SS-6
Tobacco-Use Behaviors	NCCDPHP	1994; Vol. 43, No. SS-3
Spina Bifida	NCEH	1996; Vol. 45, No. SS-2
Streptococcal Disease (Group B)	NCID	1992; Vol. 41, No. SS-6
Sudden Unexplained Death Syndrome Among Southeast Asian Refugees	NCEHIC, NCPS	1987; Vol. 36, No. 1SS
Suicides, Persons 15-24 Years of Age	NCEHIC	1988; Vol. 37, No. SS-1
Syphilis, Congenital	NCPS	1993; Vol. 42, No. SS-6
Syphilis, Primary & Secondary	NCPS	1993; Vol. 42, No. SS-3
Tetanus	NIP	1997; Vol. 46, No. SS-2
Trichinosis	NCID	1991; Vol. 40, No. SS-3
Tuberculosis	NCPS	1991; Vol. 40, No. SS-3
Waterborne Disease Outbreaks	NCID	1996; Vol. 45, No. SS-1
Years of Potential Life Lost	EPO	1992; Vol. 41, No. SS-6
Youth Risk Behaviors	NCCDPHP	1996; Vol. 45, No. SS-4

Malaria Surveillance — United States, 1994

S. Patrick Kachur, M.D., M.P.H.,
Megan E. Reller, M.D.C.M., Ann M. Barber,
Lawrence M. Barat, M.D., M.P.H., Emilia H.A. Koumans, M.D.,
Monica E. Parise, M.D., Jacqueline Roberts, M.S.,
Trenton K. Ruebush II, M.D., Jane R. Zucker, M.D., M.Sc.
*Division of Parasitic Diseases
National Center for Infectious Diseases*

Abstract

Problem/Condition: Malaria is caused by infection with one of four species of *Plasmodium* (i.e., *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*), which are transmitted by the bite of an infective female *Anopheles* sp. mosquito. Most malarial infections in the United States occur in persons who have traveled to areas (i.e., other countries) in which disease transmission is ongoing. However, cases are transmitted occasionally through exposure to infected blood products, by congenital transmission, or by local mosquitoborne transmission. Malaria surveillance is conducted to identify episodes of local transmission and to adapt prevention recommendations.

Reporting Period Covered: Cases with onset of symptoms during 1994.

Description of System: Malaria cases confirmed by blood smear are reported to local and/or state health departments by health-care providers and/or laboratories. Case investigations are conducted by local and/or state health departments, and the reports are transmitted to CDC through the National Malaria Surveillance System (NMSS), which was the source of data for this report. Numbers of cases reported through NMSS may differ from those reported through other passive surveillance systems because of differences in the collection and transmission of data.

Results: CDC received reports of 1,014 cases of malaria with onset of symptoms during 1994 among persons in the United States or one of its territories. This number represented a 20% decrease from the 1,275 cases reported for 1993. *P. vivax*, *P. falciparum*, *P. malariae*, and *P. ovale* accounted for 44%, 44%, 4%, and 3% of cases, respectively. More than one species was present in five persons (<1% of the total number of patients). The infecting species was not determined in 50 (5%) cases. The number of reported malaria cases in U.S. military personnel decreased by 86% (i.e., from 278 cases in 1993 to 38 cases in 1994). Of the U.S. civilians who acquired malaria during travel to foreign countries, 18% had followed a chemoprophylactic drug regimen recommended by CDC for the area to which they had traveled. Five persons became infected while in the United States; the infection was transmitted to two of these persons through transfusion of infected blood products. The remaining three cases, which occurred in Houston, Texas, were probably locally acquired mosquitoborne infections. Four deaths were attributed to malaria.

Interpretation: The 20% decrease in the number of malaria cases from 1993 to 1994 resulted primarily from an 86% decrease in cases among U.S. military personnel after withdrawal from Somalia. Because most malaria cases acquired in Somalia during 1993 resulted from infection with *P. vivax*, there was a proportionately greater

decrease during 1994 in the number of cases caused by *P. vivax* relative to those caused by *P. falciparum*.

Actions Taken: Additional information was obtained concerning the four fatal cases and the five cases acquired in the United States. Malaria prevention guidelines were updated and distributed to health-care providers. Persons traveling to a geographic area in which malaria is endemic should take the recommended chemoprophylactic regimen and should use protective measures to prevent mosquito bites. Persons who have a fever or influenza-like illness after returning from a malarious area should seek medical care; medical evaluation should include a blood smear examination for malaria. Malarial infections can be fatal if not promptly diagnosed and treated. Recommendations concerning prevention and treatment of malaria can be obtained from CDC.

INTRODUCTION

Malaria is caused by infection with any of four species of *Plasmodium* (i.e., *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*). The infection is transmitted by the bite of an infective female *Anopheles* sp. mosquito. Forty percent of the world's population live in areas where malaria is transmitted (e.g., parts of Africa, Asia, Central America, Hispaniola, North America, Oceania, and South America). In the past, malaria was endemic throughout much of the continental United States; an estimated 600,000 cases occurred during 1914 (1). During the late 1940s, a combination of improved socioeconomic conditions, water management, vector-control efforts, and case management was successful at interrupting malaria transmission in the United States. Since then, malaria case surveillance has been maintained to detect locally acquired cases that could indicate the reintroduction of transmission.

Through 1994, almost all cases of malaria diagnosed in the United States were imported from regions of the world where malaria transmission occurred. Each year, however, several congenital infections and infections resulting from exposure to blood or blood products have been reported in the United States. In addition, limited numbers of cases have been reported that may have been acquired through local mosquitoborne transmission (2).

State and/or local health departments and CDC thoroughly investigate all malaria cases acquired in the United States, and CDC conducts an analysis of all imported cases to detect trends in acquisition. This information is used to adapt malaria prevention recommendations for travelers abroad. For example, an increase in *P. falciparum* malaria among U.S. travelers to Africa, an area with increasing incidence of chloroquine resistance, prompted CDC in 1990 to change the recommended chemoprophylaxis from chloroquine to mefloquine (3).

The signs and symptoms of malaria are variable, but most patients have fever. Other common symptoms include headache, back pain, chills, increased sweating, myalgia, nausea, vomiting, diarrhea, and cough. The diagnosis of malaria should be considered for any person who has these symptoms and who has traveled to an area in which malaria is transmitted. Malaria also should be considered in the differential diagnosis of illness in persons who have a fever of unknown origin, regardless of their travel history. Untreated *P. falciparum* infections can progress to coma, renal failure, pulmonary edema, and death. Asymptomatic parasitemia can occur among long-term

residents of malaria-endemic areas. This report summarizes malaria cases with symptom onset in 1994 reported to CDC through the National Malaria Surveillance System (NMSS).

METHODS

Sources of Data

Data regarding malaria cases are reported to both NMSS and the National Notifiable Diseases Surveillance System. Although both systems rely on passive reporting, the numbers of reported cases may differ because of differences in the collection and transmission of data. In addition, NMSS receives more detailed clinical and epidemiologic data regarding each case (e.g., information concerning the area to which the infected person has traveled). Malaria cases that have been confirmed by blood smear are identified by health-care providers and/or laboratories. Each slide-confirmed case is reported to local and/or state health departments and to CDC through NMSS on a uniform case report form that contains clinical, laboratory, and epidemiologic information. CDC staff review all report forms at the time of receipt and request additional information if necessary (e.g., when no recent travel to a malaria-endemic country is reported). Other cases are recorded when health-care providers directly phone CDC to request assistance with the diagnosis and treatment of malaria. All cases that have been acquired in the United States are fully investigated, including all induced and congenital cases and possible introduced or cryptic cases. Information derived from uniform case report forms is entered into a computer data base and analyzed annually.

Definition of Terms

The following definitions are used in this report:

- **Laboratory criteria for diagnosis:** Demonstration of malaria parasites in blood films.
- **Confirmed case:** An episode of microscopically confirmed malaria parasitemia in any person (symptomatic or asymptomatic) diagnosed in the United States, regardless of whether the person experienced previous episodes of malaria while outside the country. A subsequent attack of malaria is counted as an additional case if the demonstrated *Plasmodium* species differs from the initially identified species. A subsequent attack of malaria occurring in a person while in the United States could indicate a relapsing infection or treatment failure resulting from drug resistance if the demonstrated *Plasmodium* species is the same species identified previously.

This report also uses terminology derived from the recommendations of the World Health Organization (4). Definitions of the following terms are included for reference:

- **Autochthonous malaria:**
 - **Indigenous.** Malaria acquired by mosquito transmission in an area where malaria is a regular occurrence.
 - **Introduced.** Malaria acquired by mosquito transmission from an imported case in an area where malaria is not a regular occurrence.
- **Imported malaria:** Malaria acquired outside a specific area. In this report, imported cases are those acquired outside the United States and its territories (i.e., Puerto Rico, Guam, and the U.S. Virgin Islands).
- **Induced malaria:** Malaria acquired through artificial means (e.g., blood transfusion or common syringes).
- **Relapsing malaria:** Renewed manifestation (i.e., of clinical symptoms and/or parasitemia) of malarial infection that is separated from previous manifestations of the same infection by an interval greater than the usual periodicity of the paroxysms.
- **Cryptic malaria:** An isolated case of malaria that can not be epidemiologically linked to additional cases.

Microscopic Diagnosis of Malaria

The early diagnosis of malaria requires that physicians consider malaria in the differential diagnosis of illness in every patient who has fever; the evaluation of such a patient should include taking a comprehensive travel history. If malaria is suspected, a Giemsa-stained smear of the patient's peripheral blood should be examined for parasites. Thick and thin blood smears must be prepared properly because the accuracy of diagnosis depends on the quality of the blood film and the experience of the laboratory personnel.* (See Appendix A for proper procedures necessary for accurately diagnosing malaria.)

RESULTS

General Surveillance

CDC received reports of 1,014 malaria cases that had onset of symptoms during 1994 among persons in the United States and its territories, representing a 20% decline from the 1,275 cases reported for 1993 (5). In 1994, five of the 1,014 persons acquired malaria while in the United States compared with 11 of 1,275 persons in 1993.

*To confirm the diagnosis of questionable cases and to obtain appropriate treatment recommendations, contact either the state or local health department or CDC's National Center for Infectious Diseases, Division of Parasitic Diseases, Malaria Section; telephone (770) 488-7760.


Since 1973, malaria in civilians has accounted for most cases reported to CDC (Table 1). During 1994, 524 cases occurred in U.S. civilians compared with 519 cases reported for 1993 (Figure 1). The number of cases in foreign civilians decreased by 18%, from 453 cases in 1993 to 370 cases in 1994. Among U.S. military personnel, the 38 cases reported in 1994 constituted an 86% decrease from the 278 cases in 1993. Eighty-four percent of the cases among U.S. military personnel in 1993 were acquired during deployment in Somalia (5). Among military personnel, the number of cases reported in 1994 (i.e., 38) was similar to the number of cases reported in the years before the large-scale deployment in Somalia.

TABLE 1. Number of malaria cases* in U.S. and foreign civilians and U.S. military personnel — United States, 1966–1994

Year	U.S. military personnel	U.S. civilians	Foreign civilians	Unknown	Total
1966	621	89	32	22	764
1967	2,699	92	51	15	2,857
1968	2,567	82	49	0	2,698
1969	3,914	90	47	11	4,062
1970	4,096	90	44	17	4,247
1971	2,975	79	69	57	3,180
1972	454	106	54	0	614
1973	41	103	78	0	222
1974	21	158	144	0	323
1975	17	199	232	0	448
1976	5	178	227	5	415
1977	11	233	237	0	481
1978	31	270	315	0	616
1979	11	229	634	3	877
1980	26	303	1,534	1	1,864
1981	21	273	809	0	1,103
1982	8	348	574	0	930
1983	10	325	468	0	803
1984	24	360	632	0	1,016
1985	31	446	568	0	1,045
1986	35	410	646	0	1,091
1987	23	421	488	0	932
1988	33	550	440	0	1,023
1989	35	591	476	0	1,102
1990	36	558	504	0	1,098
1991	22	585	439	0	1,046
1992	29	394	481	6	910
1993	278	519	453	25	1,275
1994	38	524	370	82	1,014

*An episode of microscopically confirmed malaria parasitemia in any person (symptomatic or asymptomatic) diagnosed in the United States, regardless of whether the person experienced previous episodes of malaria while outside the country. A subsequent attack of malaria occurring in a person is counted as an additional case if the demonstrated *Plasmodium* species differs from the initially identified species. A subsequent attack of malaria occurring in a person while in the United States could indicate a relapsing infection or treatment failure resulting from drug resistance if the demonstrated *Plasmodium* species is the same species identified previously.

FIGURE 1. Number of malaria cases in U.S. and foreign civilians — United States,* 1967–1994†



*Includes Puerto Rico, the U.S. Virgin Islands, and Guam.

†The substantial increase in the number of cases reported for 1980 primarily reflects cases diagnosed in immigrants from Southeast Asia after the Vietnam conflict.

Plasmodium Species

The infecting species of *Plasmodium* was identified in 964 (95%) of the 1,014 cases in 1994 (Table 2). *P. vivax* and *P. falciparum* were identified in blood smears from 43.5% and 43.6% of infected persons, respectively. The 441 *P. vivax* cases reported in 1994 represented a 33% decrease from the 663 cases in 1993. The 442 *P. falciparum* cases reported in 1994 represented a 3% decrease from the 457 cases in 1993.

Area of Acquisition and of Diagnosis

Most of the imported malaria cases had been acquired in Africa (517 [51%] cases) and Asia (253 [25%] cases) (Table 3). In comparison with 1993, 234 fewer reported cases were acquired in Africa during 1994; this decline primarily reflected the decrease in the number of cases acquired by military personnel in Somalia. The number of cases acquired in Asia remained stable from 1993 (259 cases) to 1994 (253 cases).

In the United States, cases are reported by the state in which they are diagnosed (Figure 2). Seventy-four cases were reported from New York State (excluding New York City) in 1994, representing a 61% decrease from the 191 cases in 1993. In 1993, 107 of the cases reported from New York State occurred in military personnel returning from Somalia. New York City, which began reporting cases to CDC in 1993, reported 107 cases for 1994, compared with 130 in 1993.

TABLE 2. Number of malaria cases, by *Plasmodium* species — United States, 1993 and 1994

<i>Plasmodium</i> species	1993		1994	
	No.	(%)	No.	(%)
<i>P. vivax</i>	663	(52.0)	441	(43.5)
<i>P. falciparum</i>	457	(35.8)	442	(43.6)
<i>P. malariae</i>	53	(4.2)	43	(4.2)
<i>P. ovale</i>	41	(3.2)	34	(3.4)
Undetermined	59	(4.6)	50	(4.9)
Mixed	2	(0.2)	4	(0.4)
Total	1,275	(100.0)	1,014	(100.0)

Interval Between Arrival and Onset of Illness

The infecting *Plasmodium* species and the interval between arrival in the United States and the onset of illness were known for 748 (74%) persons who had malaria. Symptoms began after arrival in the United States for 687 (92%) of these persons. Clinical malaria developed within 29 days after arrival in 284 (90%) of the 314 *P. falciparum* cases and in 83 (26%) of the 319 *P. vivax* cases (Table 4). Only 25 (4%) of the 687 persons became ill >1 year after arriving in the United States. An additional 61 persons reported becoming ill before arriving in the United States. Symptoms developed within 1 week before arrival in 37 (61%) of these persons; the remaining 24 persons reported that symptoms began 8–89 days before arrival.

Imported Malaria Cases

Imported Malaria in Military Personnel

Thirty-eight cases of imported malaria in U.S. military personnel were reported for 1994. Seventeen of these cases occurred in personnel of the U.S. Army; seven cases, the U.S. Marine Corps; eight cases, the U.S. Air Force; and four cases, the U.S. Navy. Two cases occurred in military personnel for whom the service branch was not identified.

Imported Malaria in Civilians

A total of 889 imported malaria cases occurred in civilians (Table 5). Of these, 519 (58%) cases occurred in U.S. residents, and 370 (42%) occurred in residents of other countries. Of the 519 U.S. civilians who had imported malaria, 303 (58%) had traveled to Africa, representing a 10% increase over the 276 cases acquired in this region during 1993. Of the imported cases that occurred in U.S. civilians in 1994, 102 (20%) had been acquired in Asia. Of the 370 imported cases among foreign civilians, 173 (47%) had been acquired in Africa and 128 (35%) in Asia.

Use of Antimalarial Chemoprophylaxis

Information concerning use of chemoprophylaxis was known for 487 (94%) of the 519 U.S. civilians who had imported malaria. Of these 487 persons, 257 (53%) had not taken chemoprophylaxis and 105 (22%) had not taken a drug recommended by CDC

TABLE 3. Number of malaria cases, by *Plasmodium* species and area of acquisition — United States, 1994

Area of acquisition	<i>Plasmodium</i> species						Total
	<i>P. vivax</i>	<i>P. falciparum</i>	<i>P. malariae</i>	<i>P. ovale</i>	Mixed	Unknown	
AFRICA	40	380	32	33	1	31	517
Algeria	0	1	0	0	0	0	1
Angola	0	3	0	0	0	0	3
Benin	1	1	0	0	0	0	2
Botswana	0	1	0	0	0	0	1
Burkina Faso	0	2	0	0	0	0	2
Cameroon	0	2	2	2	0	0	6
Central African Republic	0	2	0	0	0	0	2
Chad	0	4	0	0	0	0	4
Congo	0	2	0	1	0	0	3
Djibouti	0	0	0	0	0	0	0
Egypt	1	0	0	0	0	0	1
Equatorial Guinea	0	0	0	0	0	0	0
Ethiopia	4	0	0	0	0	0	4
Gabon	0	1	0	0	0	1	2
Gambia	0	10	0	0	0	0	10
Ghana	2	47	5	3	0	4	61
Guinea	0	4	0	0	0	1	5
Guinea-Bissau	0	0	0	0	0	0	0
Ivory Coast	0	14	1	2	0	4	21
Kenya	5	16	1	6	0	4	32
Liberia	1	11	3	1	0	4	20
Madagascar	3	0	0	0	0	0	3
Malawi	0	2	0	0	0	0	2
Mali	0	5	0	0	0	0	5
Mauritania	0	0	0	0	0	0	0
Mozambique	0	1	0	0	0	0	1
Niger	0	0	0	0	0	0	0
Nigeria	2	136	12	6	0	9	165
Rwanda	0	0	0	0	1	0	1
Senegal	0	5	2	0	0	0	7
Sierra Leone	2	10	0	1	0	0	13
Somalia	6	1	1	0	0	0	8
South Africa	0	3	0	0	0	0	3
Sudan	6	6	0	0	0	1	13
Tanzania	0	2	0	0	0	1	3
Togo	0	3	0	0	0	0	3
Uganda	0	7	0	3	0	0	10
Zaire	1	9	0	0	0	0	10
Zambia	1	3	0	0	0	0	4
Zimbabwe	0	1	0	0	0	0	1
Africa, Central*	0	4	0	0	0	0	4
Africa, East*	3	16	1	3	0	0	23
Africa, South*	0	0	0	1	0	0	1
Africa, West*	0	16	0	1	0	1	18
Africa, Unspecified*	2	29	4	3	0	1	39
ASIA	204	30	6	0	1	12	253
Afghanistan	0	0	0	0	0	0	0
Bangladesh	1	0	0	0	0	0	1
Cambodia	0	0	0	0	0	0	0
China	0	0	0	0	0	0	0
India	153	23	4	0	1	8	189
Indonesia	8	0	1	0	0	1	10
Laos	2	2	0	0	0	0	4

TABLE 3. Number of malaria cases, by *Plasmodium* species and area of acquisition — United States, 1994 — Continued

Area of acquisition	<i>Plasmodium</i> species						Total
	<i>P. vivax</i>	<i>P. falciparum</i>	<i>P. malariae</i>	<i>P. ovale</i>	Mixed	Unknown	
ASIA (cont'd)							
Malaysia	0	0	0	0	0	0	0
Myanmar (Burma)	1	0	0	0	0	1	2
Nepal	0	0	0	0	0	0	0
Pakistan	17	3	0	0	0	0	20
Philippines	2	0	0	0	0	0	2
Saudi Arabia	0	0	0	0	0	0	0
Sri Lanka	1	1	1	0	0	0	3
Thailand	0	0	0	0	0	0	0
Vietnam	10	1	0	0	0	1	12
Yemen	0	0	0	0	0	0	0
Asia, Southeast*	3	0	0	0	0	0	3
Asia, Unspecified*	6	0	0	0	0	1	7
Middle East, Unspecified*	0	0	0	0	0	0	0
CENTRAL AMERICA AND CARIBBEAN	119	21	3	0	1	2	146
Belize	7	0	1	0	0	0	8
Caribbean, Unspecified*	0	0	0	0	0	0	0
Costa Rica	4	0	1	0	0	0	5
Cuba	0	1	0	0	0	0	1
Dominican Republic	0	1	0	0	0	0	1
El Salvador	4	0	0	0	0	0	4
Guatemala	19	2	1	0	0	0	22
Haiti	0	9	0	0	0	0	9
Honduras	55	6	0	0	1	1	63
Nicaragua	15	2	0	0	0	0	17
Panama	0	0	0	0	0	1	1
Central America, Unspecified*	15	0	0	0	0	0	15
NORTH AMERICA	14	2	0	0	0	2	18
Canada	0	0	0	0	0	0	0
Mexico	11	0	0	0	0	2	13
United States	3	2	0	0	0	0	5
SOUTH AMERICA	13	0	1	0	1	0	15
Brazil	8	0	0	0	0	0	8
Colombia	1	0	0	0	0	0	1
Ecuador	0	0	0	0	0	0	0
French Guiana	0	0	0	0	0	0	0
Guyana	0	0	0	0	1	0	1
Peru	2	0	0	0	0	0	2
Venezuela	1	0	0	0	0	0	1
South America, Unspecified*	1	0	1	0	0	0	2
OCEANIA	25	1	0	1	0	0	27
Papua New Guinea	17	1	0	1	0	0	19
Solomon Islands	8	0	0	0	0	0	8
Vanuatu	0	0	0	0	0	0	0
Oceania, Unspecified*	0	0	0	0	0	0	0
Unknown*	26	8	1	0	0	3	38
Total	441	442	43	34	4	50	1,014

* Country unspecified.


TABLE 4. Number of imported malaria cases, by *Plasmodium* species and by interval between date of arrival in the country and onset of illness — United States, 1994

Interval (days)	<i>Plasmodium</i> species									
	<i>P. vivax</i>		<i>P. falciparum</i>		<i>P. malariae</i>		<i>P. ovale</i>		Total	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
0- 29	83	(26.0)	284	(90.4)	20	(64.5)	4	(17.4)	391	(56.9)
30- 89	67	(21.0)	21	(6.7)	4	(12.9)	7	(30.4)	99	(14.4)
90-179	75	(23.5)	6	(1.9)	5	(16.1)	6	(26.1)	92	(13.4)
180-364	74	(23.2)	2	(0.6)	1	(3.2)	3	(13.0)	80	(11.6)
≥365	20	(6.3)	1	(0.3)	1	(3.2)	3	(13.0)	25	(3.6)
Total	319	(100.0)	314	(100.0)	31	(100.0)	23	(100.0)	687	(100.0)

for the area visited. Eighty-six (18%) persons had taken a medication recommended by CDC (6). Of these persons, 69 had taken mefloquine weekly; three had taken doxycycline daily; and 14, who had traveled only in areas where chloroquine-resistant malaria has not been documented, had taken chloroquine weekly.

Of the 86 malaria cases that developed in persons who had taken a recommended antimalarial drug, 44 (51%) were caused by *P. vivax* or *P. ovale* and occurred ≥45 days after the person arrived in the United States. These cases were consistent with relapsing infections and, thus, did not indicate failures of prophylaxis. Information

FIGURE 2. Number of malaria cases, by state in which the disease was diagnosed* — United States, 1994



*Of the 1,014 malaria cases reported for 1994, only five cases had been acquired in the United States. Two of these cases had been acquired through transfusion of blood or blood products, and three were probably mosquitoborne.

TABLE 5. Number of imported malaria cases in U.S. and foreign civilians, by area of acquisition — United States, 1994

Area of acquisition	U.S. civilians		Foreign civilians		Total	
	No.	(%)	No.	(%)	No.	(%)
Africa	303	(58.4)	173	(46.8)	476	(53.5)
Asia	102	(19.7)	128	(34.6)	230	(25.9)
Caribbean	5	(1.0)	4	(1.1)	9	(1.0)
Central America	62	(11.9)	43	(11.6)	105	(11.9)
Mexico	7	(1.3)	5	(1.4)	12	(1.3)
Oceania	24	(4.6)	3	(0.8)	27	(3.1)
South America	9	(1.7)	3	(0.8)	12	(1.3)
Unknown	7	(1.3)	11	(3.0)	18	(2.0)
Total	519	(100.0)	370	(100.0)	889	(100.0)

TABLE 6. Number of imported malaria cases in U.S. civilians, by purpose of travel at the time of acquisition — United States, 1994

Category	Imported cases	
	No.	(%)
Business representative	35	(6.7)
Government employee	4	(0.8)
Missionary	48	(9.2)
Peace Corps worker	5	(1.0)
Refugee	3	(0.6)
Sailor	5	(1.0)
Teacher/Student	50	(9.6)
Tourist	52	(10.0)
Visitor of a friend or relative	60	(11.6)
Other	14	(2.7)
Unknown	243	(46.8)
Total	519	(100.0)

was insufficient to assess whether six cases of *P. vivax* malaria were relapsing infections. Only four cases of *P. vivax* malaria occurred within 45 days after the person returned to the United States. The remaining 32 malaria cases that occurred in persons who had taken a recommended antimalarial drug for chemoprophylaxis included 24 cases of *P. falciparum*, two cases of *P. malariae*, and six cases in which the infecting species was not identified. The two cases of *P. malariae* both occurred >45 days after the person returned to the United States and may represent late recrudescence of *P. malariae* infection.

Of the 86 persons who reported having taken a recommended antimalarial drug for chemoprophylaxis, information concerning the dosing regimen was available for 20 (23%). Thirteen (65%) of these 20 persons reported that they had taken incorrect or irregular doses of the recommended medications. Only seven (35%) of those who had taken a recommended drug for the area in which they had traveled also reported correctly following the dosing regimen.

The purpose of travel to malaria-endemic areas was reported for 276 (53%) of the 519 U.S. civilians who had imported malaria (Table 6). Of these, the largest percentage (12%) had traveled to visit a friend or relative.

Malaria Acquired in the United States

Congenital Malaria

No cases of congenital malaria were reported for 1994.

Cryptic Malaria

Three cases of cryptic malaria were reported for 1994. All three persons acquired *P. vivax* infection in Houston, Texas, through presumed mosquitoborne transmission (7).

Case 1. On July 8, 1994, a 62-year-old man was hospitalized in Houston because of an 8-day history of fever, chills, increased sweating, and vomiting. His temperature at the time of admission was 104.0 F (40.0 C). On July 11, *P. vivax* parasites were identified on a peripheral blood smear. The man did not have a history of blood transfusions, intravenous-drug use, tattoos, or previous malarial infection. He had not traveled to a malaria-endemic area since 1956. He recovered after treatment with chloroquine and primaquine.

Case 2. On July 8, 1994, a 37-year-old man was admitted to a different hospital in Houston because of fever, chills, increased sweating, headache, shortness of breath, nausea, and vomiting of 3 weeks' duration. He reported no travel outside of the United States, blood transfusions, tattoos, or previous malarial infection. He had not used intravenous drugs for at least 8 years before this illness. He slept in a shack without screens behind a relative's house. At the time of admission to the hospital, he had a fever of 102.8 F (39.3 C). *P. vivax* parasites were identified on a routine peripheral blood smear. The man recovered after initial treatment with chloroquine; he received primaquine during the investigation in August to prevent possible relapse.

Case 3. On December 4, 1994, a 50-year-old man was hospitalized in Houston because of a 2-week history of altered mental status, fever, and headache; his temperature at the time of hospital admission was 100.0 F (37.8 C). An examination of a peripheral blood smear demonstrated the presence of *P. vivax* parasites. The man recovered after treatment with chloroquine and primaquine. He had been hospitalized twice at two different hospitals in August 1994 because of similar symptoms that had begun during July and early August. During the second admission, his illness was diagnosed as viral meningitis; one thick blood smear obtained on August 23 was reported as being negative for malarial parasites, and acute- and convalescent-phase immunoglobulin M enzyme-linked immunosorbent assay titers for St. Louis encephalitis were negative. The blood smear obtained on August 23 was unavailable for review by CDC; however, serum samples from the hospitalizations in August and December were tested for malarial antibody by an indirect immunofluorescent assay. The serologic test was positive for *P. vivax* (titers of 1:64, 1:256, and 1:256 on August 23, August 30, and December 6, respectively). These results suggested that the *P. vivax* infection

occurred before December and that the episode in December was likely a relapse, which can only result from mosquitoborne transmission and not from person-to-person transmission via blood products. Because the man had not traveled to a malaria-endemic country, local mosquitoborne transmission was likely the cause of the initial infection.

These three cases were linked geographically and temporally. All three persons resided within a 3-mile radius of one another and first became ill in July. They were not acquainted and had had no previous contact with one another. All three had prolonged nighttime exposures to mosquitoes. On August 4, adult *Anopheles quadrimaculatus* mosquitoes (i.e., competent potential vectors of malaria) were trapped near the residences of the patients described in cases 1 and 2, although no active breeding sites were identified at that time.

Induced Malaria

Two cases of transfusion-induced malaria were reported for 1994. Both cases occurred in Texas.

Case 1. Between March 24 and April 1, 1994, a 59-year-old woman who lived in Houston received 8 units of packed red blood cells. On April 20, she became ill with fever and disseminated intravascular coagulation; an examination of a peripheral blood smear demonstrated the presence of *P. falciparum* parasites (7% of red blood cells were infected). The diagnosis was confirmed microscopically at CDC. She did not have a history of travel to malaria-endemic areas, and she reported no previous malarial infection. She was treated with quinine and doxycycline and recovered without complications. Serum specimens were obtained from seven of eight donors of the blood that the woman had received in early March and April. One donor could not be located. Serum specimens from six donors were negative for antimalarial antibodies. Serum from the remaining donor was positive for *P. falciparum* antibodies (1:4,096). When this donor was questioned, he reported having had a malarial infection in 1991 and having resided in Nigeria during 1988–1992. The donor had no symptoms of acute malaria at the time of the interview, and no parasites were detected on his peripheral blood smear. He was treated with quinine and tetracycline.

Case 2. On October 23, 1994, a 46-year-old man underwent cardiac surgery at a hospital in Houston. During his hospitalization, he received 7 units of packed red blood cells and 2 units of fresh frozen plasma. On November 9, he was readmitted because of a 6-day history of fever and a surgical wound infection. On November 16, an examination of a peripheral blood smear demonstrated the presence of *P. falciparum* parasites (24% of red blood cells were infected); this diagnosis was confirmed by CDC. The man had not traveled to a malaria-endemic area. He was treated initially with chloroquine, which was changed to quinine and doxycycline after *P. falciparum* infection was confirmed.

Serum samples were obtained from six of the seven persons who had donated the packed red blood cells. One donor could not be located. Serum samples from five donors were negative for antimalarial antibodies by immunofluorescent antibody assay. Serum from the remaining donor was positive for antibodies to *P. falciparum* (1:4,096). This donor had lived in Ghana for several years and had returned to the

United States in 1992. An examination of the donor's peripheral blood smear at the time of the investigation did not demonstrate the presence of malarial parasites. He was treated with quinine and sulfadoxine-pyrimethamine.

Deaths attributed to Malaria

During 1994, four deaths were attributed to malaria.

Case 1. A 47-year-old man became ill 1 week after returning to his residence in Florida following a 3-week visit to Haiti, where he had been born. He was evaluated at a hospital emergency department because of a 3-day history of fever and lower back pain, at which time his illness was diagnosed as a viral illness. He had not taken antimalarial chemoprophylaxis during his trip. He was treated with amoxicillin, acetaminophen, and codeine and was not hospitalized. He returned to the hospital 24 hours later because of recurrent fever and chills and unabated back pain, and he was admitted because of a suspected dissecting aortic aneurysm. An examination of a peripheral blood smear at the time of admission demonstrated the presence of *P. falciparum* parasites. He was treated with intravenous quinidine gluconate, and then oral quinine sulfate combined with oral doxycycline. On November 30, he had hypotension, acute renal failure, and disseminated intravascular coagulation. He died on December 1.

Case 2. On October 4, 1994, a 59-year-old man who had been born in Asia and who resided in New York returned from India. He had not taken antimalarial chemoprophylaxis during his trip. He had a past history of aortic and mitral valve replacement. On October 6, he was admitted to a hospital in New York because of a 9-day history of fever, chills, jaundice, and myalgia; his illness was diagnosed as bacterial endocarditis and severe respiratory failure requiring mechanical ventilation. An examination of the man's blood smear at the time of admission demonstrated the presence of *P. falciparum*, and treatment with intravenous quinidine gluconate and doxycycline was initiated. During the next 2 days, cerebral malaria and renal failure developed in the man. On October 11, he became comatose after a cardiac arrest. He died on October 19. A postmortem examination demonstrated evidence of anoxic encephalopathy, acute renal failure, and prosthetic aortic and mitral valve endocarditis. The cause of death was determined to be anoxic encephalopathy secondary to cerebral malaria.

Case 3. On June 7, 1994, a 27-year-old man was hospitalized in San Juan, Puerto Rico, because of a 1-week history of fever, chills, vomiting, and diarrhea. He had arrived in Puerto Rico from the Dominican Republic 2 weeks earlier. A physical examination of the man at the time of admission indicated only mild jaundice. His hemoglobin was 9.3 g/dL; white blood cell count, 8,900; platelet count, 16,000; and bilirubin, 2.8 mg/dL. The illness was diagnosed initially as bacterial gastroenteritis, and he was treated with antibiotics. On June 9, he had renal failure, and an examination of his peripheral blood films demonstrated the presence of *P. falciparum* parasitemia (>50% of erythrocytes were infected). His hemoglobin had decreased to 7.1 g/dL. Antimalarial therapy with oral quinine and doxycycline was initiated. Respiratory acidosis developed in the man, and he died the next day.

Case 4. During November 1993, a 74-year-old man returned to his residence in California after a trip to India. He had been born in Asia, and he traveled frequently between India and his residence. He had not taken antimalarial prophylaxis during his most recent trip, despite a previous history of malaria in India in June 1993. On January 27, 1994, he went to a local emergency department because of a 10–12 day history of dyspnea, chest pain, and recurrent fever and chills. At the time of hospital admission, an examination of the man indicated evidence of a recent myocardial infarction and ischemic cardiomyopathy. An examination of his peripheral blood smears demonstrated the presence of *P. vivax* infection, and he was treated with chloroquine and primaquine. On the second day of hospitalization, respiratory distress requiring mechanical ventilation developed. On February 3, no malarial parasites were seen on thick or thin blood smears. That day, the man had cardiogenic shock and died 24 hours later. No autopsy was performed. Although the *P. vivax* infection may have contributed to the complicated clinical course of the man's illness, it is unlikely that malaria was the immediate cause of death. Unlike *P. falciparum* infection, *P. vivax* infection is seldom fatal, and myocardial dysfunction is not a recognized complication of parasitemia.

DISCUSSION

A total of 1,014 cases of malaria were reported to NMSS for 1994, representing a 20% decrease from the 1,275 cases reported for 1993. The 240 fewer cases in U.S. military personnel during 1994 (i.e., after the deployment of troops in Somalia was ended in 1993) accounted for 93% of this decrease. Although the number of cases occurring in U.S. civilians was unchanged from the 1993 level, the number of cases among foreign civilians decreased by 18%.

While the percentage of cases caused by *P. vivax* infection decreased from 52% in 1993 to 44% in 1994, the percentage caused by *P. falciparum* increased from 36% to 44%. Most of the cases acquired in Somalia in 1993 resulted from infection with *P. vivax*.

Of those U.S. civilians for whom antimalarial chemoprophylaxis information was available, only 86 (18%) infections occurred in persons who reported having taken a recommended chemoprophylactic agent while traveling abroad. An earlier review of deaths attributed to malaria in the United States identified several risk factors for fatal malaria, including failure to take recommended antimalarial chemoprophylaxis, refusal or delay in seeking medical care, and misdiagnosis (8). A combination of these factors contributed to the four deaths reported for 1994.

Treatment for malaria should be initiated immediately after the diagnosis has been confirmed by a positive blood smear. Treatment should be determined on the basis of the infecting *Plasmodium* species, the probable geographic origin of the parasite, the parasite density, and the patient's clinical status (9). Although non-*falciparum* malaria rarely causes severe illness, persons diagnosed as having *P. falciparum* infection are at risk for severe, life-threatening complications.

Health-care workers are encouraged to consult appropriate sources for malaria treatment recommendations or call CDC's National Center for Infectious Diseases, Division of Parasitic Diseases, at (770) 488-7760. Detailed recommendations for preventing malaria are available 24 hours a day from the CDC International Travelers

Hotline, which can be accessed by telephone or facsimile ([888] 232-3228) or CDC's World-Wide Web server (<http://www.cdc.gov/>). In addition, CDC annually publishes updated recommendations in the *Health Information for International Travel* (6), which is available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9235; telephone (202) 512-1800.

References

1. Pan American Health Organization. Report for registration of malaria eradication from United States of America. Washington, DC: Pan American Health Organization, 1969.
2. Zucker JR. Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. *Emerging Infectious Diseases* 1996;2:37-43.
3. Lackritz EM, Lobel HO, Howell J, Bloland P, Campbell CC. Imported *Plasmodium falciparum* malaria in American travelers to Africa: implications for prevention strategies. *JAMA* 1991;265:383-5.
4. World Health Organization. Terminology of malaria and of malaria eradication. Geneva, Switzerland: World Health Organization, 1963:32.
5. Barat LM, Zucker JR, Barber AM, et al. Malaria surveillance—United States, 1993. In: CDC surveillance summaries. *MMWR* 1997;46(No. SS-2):27-47.
6. CDC. Health information for international travel, 1995. Atlanta: US Department of Health and Human Services, Public Health Service, CDC, 1995; DHHS publication no. (CDC)95-8280.
7. CDC. Local transmission of *Plasmodium vivax* malaria—Houston, Texas, 1994. *MMWR* 1995;44:295, 301-3.
8. Greenberg AE, Lobel HO. Mortality from *Plasmodium falciparum* malaria in travelers from the United States, 1959 to 1987. *Ann Intern Med* 1990;113:326-7.
9. Zucker JR, Campbell CC. Malaria: principles of prevention and treatment. *Infect Dis Clin North Am* 1993;7:547-67.

APPENDIX


Microscopic Procedures for Diagnosing Malaria

To establish the diagnosis of malaria, a blood smear must be prepared from fresh blood obtained by pricking the finger (Figures A-1 and A-2).^{*} The thin smear is fixed in methanol before staining; the thick smear is stained unfixed. Many hospitals have a Wright-Giemsa stain available, which is acceptable; however, Wright stain alone will not reliably stain *Plasmodium* parasites. For best results, the smear should be stained with a 3% Giemsa solution (pH of 7.2) for 30–45 minutes. In *P. falciparum* infections, the parasite density should be estimated by counting the percentage of red blood cells infected—not the number of parasites—under an oil immersion lens on a thin film.

Thick blood smears are more sensitive in detecting malaria parasites because the blood is concentrated, allowing a greater volume of blood to be examined. However, thick smears are more difficult to read, and thin smears may be preferred by laboratories that have limited experience. *Plasmodium* parasites are always intracellular, and

^{*}In Figures A-1 and A-2, the hands are shown ungloved to better illustrate their placement during the procedures. However, wearing gloves while processing blood specimens is recommended to prevent transmission of bloodborne pathogens (MMWR 1988;37:377–82, 387–8 and MMWR 1987;36[No. S2]).


FIGURE A-1. Blood collection for thin or thick blood film



they demonstrate, if stained correctly, blue cytoplasm with a red chromatin dot. Common errors in reading malaria smears are caused by platelets overlying a red blood cell, concern about missing a positive slide, and misreading artifacts as parasites. Persons suspected of having malaria but whose blood smears do not demonstrate the presence of parasites should have blood smears repeated approximately every 12–24 hours for 3 consecutive days. If smears remain negative, then the diagnosis of malaria is unlikely.

For rapid diagnosis, make the thick and thin films on separate slides. Air dry the thin film, fix it with methyl alcohol, and immediately stain it. If no parasites are found on the thin film, wait until the thick film is dry and examine it for organisms that may not have been detected on the thin preparation.

FIGURE A-2. Preparation of a thin and thick blood film on the same slide



State and Territorial Epidemiologists and Laboratory Directors

State and Territorial Epidemiologists and Laboratory Directors are acknowledged for their contributions to *CDC Surveillance Summaries*. The epidemiologists listed below were in the positions shown as of July 1997, and the laboratory directors listed below were in the positions shown as of July 1997.

State/Territory	Epidemiologist	Laboratory Director
Alabama	John P. Lofgren, MD	William J. Callan, PhD
Alaska	John P. Middaugh, MD	Gregory V. Hayes, DrPH
Arizona	Robert W. England, Jr, MD, MPH	Barbara J. Erickson, PhD
Arkansas	Thomas C. McChesney, DVM	Michael G. Foreman
California	Stephen H. Waterman, MD, MPH	Paul Kimsey, PhD (Acting)
Colorado	Richard E. Hoffman, MD, MPH	Ronald L. Cada, DrPH
Connecticut	James L. Hadler, MD, MPH	Sanders F. Hawkins, PhD
Delaware	A. LeRoy Hathcock, PhD	Chris Zimmerman, MA (Acting)
District of Columbia	Martin E. Levy, MD, MPH	James B. Thomas, ScD
Florida	Richard S. Hopkins, MD, MSPH	E. Charles Hartwig, ScD
Georgia	Kathleen E. Toomey, MD, MPH	Elizabeth A. Franko, DrPH
Hawaii	Richard L. Vogt, MD	Vernon K. Miyamoto, PhD
Idaho	Christine G. Hahn, MD	Richard H. Hudson, PhD
Illinois	Byron J. Francis, MD, MPH	David F. Carpenter, PhD
Indiana	Gregory K. Steele, DrPH, MPH	David E. Nauth (Acting)
Iowa	M. Patricia Quinlisk, MD, MPH	Mary J. R. Gilchrist, PhD
Kansas	Gianfranco Pezzino, MD, MPH	Roger H. Carlson, PhD
Kentucky	Clarkson T. Palmer, MD, MPH (Acting)	Thomas E. Maxson, DrPH
Louisiana	Louise McFarland, DrPH	Henry B. Bradford, Jr, PhD
Maine	Kathleen F. Gensheimer, MD, MPH	Philip W. Haines, DrPH
Maryland	Diane M. Dwyer, MD, MPH	J. Mehnen Joseph, PhD
Massachusetts	Alfred DeMaria, Jr, MD	Ralph J. Timperi, MPH
Michigan	Kenneth R. Wilcox, Jr, MD, DrPH	Robert Martin, DrPH
Minnesota	Michael T. Osterholm, PhD, MPH	Pauline Bouchard, JD, MPH
Mississippi	Mary Currier, MD, MPH	Joe O. Graves, PhD
Missouri	H. Denny Donnell, Jr, MD, MPH	Eric C. Blank, DrPH
Montana	Todd A. Damrow, PhD, MPH	Douglas O. Abbott, PhD
Nebraska	Thomas J. Safranek, MD	John D. Blosser
Nevada	Randall L. Todd, DrPH	Anton Sohn, MD (Acting)
New Hampshire	Jesse Greenblatt, MD, MPH	Veronica C. Malmberg, MSN
New Jersey	Faye E. Sorhage, DVM, MPH (Acting)	Thomas J. Domenico, PhD
New Mexico	C. Mack Sewell, DrPH, MS	David E. Mills, PhD
New York City	Benjamin A. Mojica, MD, MPH	Alex Ramon, MD, MPH
New York State	Perry F. Smith, MD	Ann Willey, PhD
North Carolina	J. Michael Moser, MD, MPH	Lou F. Turner, DrPH
North Dakota	Larry A. Shireley, MS, MPH	James D. Anders, MPH
Ohio	Thomas J. Halpin, MD, MPH	Leona Ayers, MD
Oklahoma	J. Michael Crutcher, MD, MPH	Garry L. McKee, PhD
Oregon	David W. Fleming, MD	Michael R. Skeels, PhD, MPH
Pennsylvania	James T. Rankin, Jr, DVM, PhD, MPH	Bruce Kleger, DrPH
Rhode Island	Utpala Bandyopadhyay, MD, MPH	Walter S. Combs, PhD
South Carolina	James J. Gibson, MD, MPH	Harold Dowda, PhD
South Dakota	Susan E. Lance, DVM, PhD, MPH	Vacant
Tennessee	William L. Moore, Jr, MD	Michael W. Kimberly, DrPH
Texas	Diane M. Simpson, MD, PhD	David L. Maserang, PhD
Utah	Craig R. Nichols, MPA	Charles D. Brokopp, DrPH
Vermont	Peter D. Galbraith, DMD, MPH	Burton W. Wilcke, Jr, PhD
Virginia	Grayson B. Miller, Jr, MD, MPH	James L. Pearson, DrPH
Washington	Paul A. Stehr-Green, DrPH, MPH	Jon M. Counts, DrPH
West Virginia	Loretta E. Haddy, MA, MS	Frank W. Lambert, Jr, DrPH
Wisconsin	Jeffrey P. Davis, MD	Ronald H. Laessig, PhD
Wyoming	Gayle L. Miller, DVM, MPH	Roy J. Almeida, DrPH
American Samoa	Joseph Tufa, DSM	Edgar C. Reid, MO, MPH
Federated States of Micronesia	Vacant	—
Guam	Robert L. Haddock, DVM, MPH	Florencia Nocon (Acting)
Marshall Islands	Tom D. Kijiner	—
Northern Mariana Islands	Jose L. Chong, MD	Isamu J. Abraham, DrPH
Palau	Jill McCready, MS, MPH	—
Puerto Rico	Carmen C. Deseda, MD, MPH	Jose Luis Miranda Arroyo, MD
Virgin Islands	Josea Poblete, MD (Acting)	Norbert Mantor, PhD

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3226.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

☆U.S. Government Printing Office: 1998-633-228/67029 Region IV

DEPARTMENT OF
HEALTH AND HUMAN SERVICES
Centers for Disease Control
and Prevention (CDC)
Atlanta, Georgia 30333

Official Business
Penalty for Private Use \$300
Return Service Requested

9602 93036 971008
UNIVERSITY MICROFILMS
SERIALS ACQUISITION DEPT
300 NORTH ZEEB ROAD
ANN ARBOR MI 48103-1553

0001

ATL GA 303 16:54 10/10/97

FIRST-CLASS MAIL
POSTAGE & FEES PAID
PHS/CDC

4 4 1 0 3 4 4 5 5 3

4 4 1 0 3 4 4 5 5 3

